Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 07/20 05:35:02 pm
92.05 EUR   -0.32%
07/20BAYER : to Stop Selling Essure in U.S.
DJ
07/20BAYER : to Stop Selling Essure in U.S.
DJ
07/20Swiss, German drugmakers join U.S. price freeze
RE
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Bayer : to Stop Selling Essure in U.S.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/20/2018 | 10:11pm CEST

By Nishant Mohan

Bayer AG will stop selling its Essure birth-control device in the U.S. after this year due to declining sales, the company said Friday.

Bayer said the sales decline resulted from fewer women favoring permanent contraception over other options, as well as from "inaccurate and misleading publicity."

The U.S. is the only remaining market where the German pharmaceutical and chemicals company sells Essure. The company said in a statement it sold Essure in a total of 21 countries, but ended sales of the implant in all countries but the U.S. last year on a "lack of interest in the product."

"Our decision to discontinue sales is for business reasons, and not for any safety or efficacy concerns about Essure," the company said in a statement.

In April, the U.S. Food and Drug Administration tightened restrictions on the sale and distribution of the birth-control implant, requiring both patients and health-care providers to sign an acceptance-of-risk form.

That move followed an FDA decision in 2016 requiring Bayer to add a prominent warning to call attention to serious risks associated with the device, after studies linked it to pain and other health issues among women.

In April the FDA said since adding the warnings, Essure sales have declined about 70% in the U.S.

The company said it planned to continue enrolling Essure patients in a postmarket study and would work closely with the FDA to ensure appropriate follow-up.

Bayer said Essure, which gained FDA approval in 2002, is the only FDA-approved nonsurgical form of permanent birth control.

--Stephen Nakrosis contributed to this article.

Write to Nishant Mohan at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
07/20BAYER : to Stop Selling Essure in U.S.
DJ
07/20BAYER : to Stop Selling Essure in U.S.
DJ
07/20Swiss, German drugmakers join U.S. price freeze
RE
07/20BAYER : to phase out Essure birth control device in U.S.
RE
07/20BAYER : Voluntarily Discontinues Sales of Essure in U.S.
DJ
07/20Battle lines drawn as EU court weighs fate of gene-edited crops
RE
07/20BAYER : Reports from Bayer Add New Data to Findings in Head and Neck Cancer (EGF..
AQ
07/19REPORTS FROM BAYER PROVIDE NEW INSIG : Bioavailability, Excretion,...
AQ
07/12BAYER : Findings from Bayer in the Area of Medical Statistics Described (A Bayes..
AQ
07/12Lanxess water treatment unit attracts interest - sources
RE
More news
News from SeekingAlpha
07/20Bayer to stop Essure sales in U.S. at year-end 
07/20Allergan's Big Win For 12-Week Wet AMD Dosing With Abicipar May Be Enough To .. 
07/123 THINGS IN BIOTECH, JULY 12 : Immunotherapy Brawl, And A Creeper In The Weeds 
07/10Judge says lawsuits alleging Roundup weedkiller causes cancer can go to trial 
07/05Bayer Animal Health in-licenses IP from Mitsui Chemicals Agro for parasiticid.. 
Financials (€)
Sales 2018 39 201 M
EBIT 2018 8 014 M
Net income 2018 5 033 M
Debt 2018 34 233 M
Yield 2018 3,01%
P/E ratio 2018 18,42
P/E ratio 2019 16,31
EV / Sales 2018 3,07x
EV / Sales 2019 2,52x
Capitalization 86 121 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 116 €
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-10.06%100 917
JOHNSON & JOHNSON-9.93%337 790
PFIZER3.06%218 540
NOVARTIS-1.75%206 705
ROCHE HOLDING LTD.-5.90%200 737
MERCK AND COMPANY11.11%168 171